ABN Newswire is a business newswire and press release distribution service for listed companies on stock exchanges globally. ABN Newswire distributes company announcements to the professional platforms, finance portals and syndicates important corporate news to a wide variety of news aggregators and financial news systems.
Ablynx (EBR:ABLX) * Pulmonary delivery of anti-viral Nanobodies® gives extended protection against viral infection in vivo * In vivo proof of concept for its novel proprietary half-life extension technology
GHENT, Belgium, 14 January 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today two significant advances achieved with its Nanobody® platform. In the first, it has shown that anti-viral Nanobodies® give extended protection against viral infection in vivo when administered via an intrapulmonary route. In the second, Ablynx has demonstrated in vivo proof of concept for a proprietary novel half-life(*) extension technology which allows the half-life of its Nanobody®-based therapeutics to be tailored depending on the disease indication.
Pulmonary delivery of Nanobodies® Ablynx has demonstrated that anti-viral Nanobodies® protect against signs of viral infection and presence of active virus when delivered via an intrapulmonary route. Following a single administration of the Nanobodies® via the lungs, neutralization of virus was observed for at least 72 hours.
Additionally, Ablynx has shown that Nanobodies® are suitable for systemic delivery(**) via the lungs. Their extended bioavailability is increased by a factor of five to ten times compared with intravenous administration.
Ablynx is also investigating other alternative delivery technologies for its Nanobodies® including oral to systemic delivery and needleless administration.
Novel proprietary half-life extension technology Ablynx has access to several different methods to tailor the half-life of its Nanobodies® depending on the desired characteristics of the therapeutic drug candidate and the indication. The Company announced today that they have discovered and developed a novel proprietary half-life extension technology and demonstrated in vivo results which show considerable potential to significantly increase the half-life for its Nanobodies® in humans.
Please see link below for the complete version of this press release
For more information, please contact: College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com
Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com